8-(1,1-Dioxo-1,4-thiazinan-4-yl)-5-(6-phenylpyridin-3-yl)-2,3,7,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7-tetraen-10-one | 1361297-46-2

• 英文名称: 8-(1,1-Dioxo-1,4-thiazinan-4-yl)-5-(6-phenylpyridin-3-yl)-2,3,7,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7-tetraen-10-one
• CAS: 1361297-46-2
• 化学式: C₂₄H₂₂N₆O₃S
• 分子量: 474.543
• InChiKey: VCJMKLXYJSPDKN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  34
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  118
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以72%的产率得到8-(1,1-Dioxo-1,4-thiazinan-4-yl)-5-(6-phenylpyridin-3-yl)-2,3,7,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7-tetraen-10-one
  参考文献：
  名称：

  Acid-mediated cyclizations of SEM-protected heterocyclic anilines and adjacent hydroxyls or enol-ethers

  摘要：

  Acid-mediated cyclizations of SEM-protected heterocyclic anilines and adjacent hydroxyls or enol ethers during SEM deprotection are reported. Strategies to suppress these side reactions and their potential synthetic utilities are also described. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2013.09.059

文献信息

• [EN] FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN<br/>[FR] INHIBITEURS TRICYCLIQUES CONDENSÉS DE MTOR (MAMMALIAN TARGET OF RAPAMYCIN)
  申请人：SCHERING CORP

  公开号：WO2012027234A1

  公开（公告）日：2012-03-01

  This invention relates to novel fused tricyclic compounds that are inhibitors of mammalian Target of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP, and are useful in the treatment of cellular proliferative diseases, for example cancer and other proliferative disorders.

  这项发明涉及新颖的融合三环化合物，它们是哺乳动物雷帕霉素靶点（mTOR）激酶的抑制剂，也被称为FRAP、RAFT、RAPT或SEP，并且在治疗细胞增殖性疾病方面有用，例如癌症和其他增殖性障碍。
• Fused Tricyclic Inhibitors of Mammalian Target of Rapamycin
  申请人：Meng Zhaoyang

  公开号：US20130150353A1

  公开（公告）日：2013-06-13

  This invention relates to novel fused tricyclic compounds that are inhibitors of mammalian Target of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP, and are useful in the treatment of cellular proliferative diseases, for example cancer and other proliferative disorders.

  本发明涉及一种新型的融合三环化合物，它们是哺乳动物雷帕霉素靶蛋白(mTOR)激酶的抑制剂，该蛋白也被称为FRAP、RAFT、RAPT或SEP，并且它们在治疗细胞增生性疾病，例如癌症和其他增生性疾病中有用。
• FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2608668B1

  公开（公告）日：2016-06-01
• US8703784B2
  申请人：——

  公开号：US8703784B2

  公开（公告）日：2014-04-22